Loading...
01/11 16:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report shows strong financial performance with a 16.5% revenue increase, improved gross margins, and a record high in ART cycles. Despite some uncertainties in utilization rates and macroeconomic factors, the company maintained a robust client base and expanded its offerings. The Q&A session reflected management's confidence in growth, with no slowdowns in RFP activities. Although there were some unclear responses, the overall positive financial metrics and optimistic guidance suggest a positive stock price movement, especially given the company's small-cap status.
Revenue $324 million, up 16.5% year-over-year, primarily due to an increase in the number of clients and covered lives. Excluding the impact of a large former client and a $15 million unfavorable treatment mix shift from the prior year, revenue increased 19%.
Gross Profit $76 million, up 21% year-over-year, yielding a gross margin of 23.4%, improved from 22.4% in the prior year due to the impact of the unfavorable mix shift in the year-ago period.
Adjusted EBITDA $58 million, up 15% year-over-year, with an adjusted EBITDA margin of 17.8%, which declined slightly from the year-ago period due to investments made.
Net Income $15.1 million, or $0.17 per diluted share, compared to $16.9 million, or $0.17 per share in the year-ago period, primarily due to a higher provision for income taxes.
Operating Cash Flow Nearly $50 million, nearly double the prior year period, due to higher profitability and timing of certain working capital items.
Fertility Revenue $206 million, up 22% year-over-year, reflecting a comparatively lower proportion of treatments requiring a pharmacy component.
Pharmacy Revenue $118 million, up 9% year-over-year, reflecting a lower proportion of treatments requiring a pharmacy component.
Clients 532 clients with at least 1,000 lives, compared to 451 clients in the year-ago period, indicating growth in the client base.
Covered Lives 6.7 million covered lives, up from 6.35 million in the year-ago period.
ART Cycles 16,160 cycles, up 9% year-over-year, marking the highest quarterly total ever.
Sales and Marketing Expense 5.5% of revenue, reflecting a modest improvement from the year-ago period.
G&A Expense 10.4% of revenue, slightly higher than the first quarter a year ago, due to investments in expanding the product platform.
New Product Launches: Expanded the solution by adding dual services to the comprehensive maternity offering and launched a parent and child well-being program.
Market Expansion: Continued growth in client base with 532 clients and 6.7 million covered lives, reflecting a 19% increase in revenue excluding a large client under transition.
Market Positioning: Women's health remains a priority for employers, driven by demographic shifts in family planning and increasing maternity costs.
Operational Efficiency: Generated nearly $50 million in operating cash flow, nearly double the prior year, reflecting higher profitability and effective revenue cycle management.
Strategic Shifts: Raised full year guidance for revenue to between $1.185 billion to $1.235 billion, reflecting growth of 1.5% to 5.8%.
Competitive Pressures: The employment market remains highly competitive, with nearly 600,000 jobs added since January and an unemployment rate around 4%. This competitive landscape pressures employers to provide comprehensive health care benefits to attract and retain talent.
Regulatory Issues: The company acknowledges the risks and uncertainties associated with their business, which may include regulatory changes that could impact operations and financial performance.
Supply Chain Challenges: The company is investing in expanding its product portfolio and platform, which may face supply chain challenges that could affect the timely delivery of services and products.
Economic Factors: The guidance for the remainder of the year reflects uncertainty in the macro environment, which could impact client decisions and overall business performance.
Client Retention and Acquisition: The company faces risks related to its ability to acquire new clients and retain existing ones, particularly in light of changing market dynamics and client needs.
Utilization Rates: There is potential variability in member engagement and utilization rates, which could affect revenue projections and overall financial performance.
Growth Initiatives: Progyny has made meaningful progress in laying the foundation for future growth through channel partnerships and investments to expand its product portfolio and platform.
Market Positioning: The company is focused on enhancing member experience and extending its leading position in women's health and family building.
Service Expansion: Progyny has expanded its solution offerings, including dual services to its maternity offering and a new parent and child well-being program.
Client Engagement: The company is seeing strong engagement levels and is well-positioned for the upcoming selling season.
Q2 2025 Revenue Guidance: Projected revenue between $310 million to $325 million, reflecting growth of 2% to 7%.
Full Year 2025 Revenue Guidance: Revenue projected between $1.185 billion to $1.235 billion, reflecting growth of 1.5% to 5.8%.
Adjusted EBITDA Guidance: Expected adjusted EBITDA between $190 million to $203 million for the full year.
Net Income Guidance: Projected net income between $42.4 million to $51.8 million for the full year.
Earnings Per Share Guidance: Expected earnings per diluted share between $0.46 and $0.56 for the full year.
Adjusted EPS Guidance: Projected adjusted EPS between $1.54 and $1.64 for the full year.
Share Repurchase Program: None
The earnings call shows a positive sentiment with strong financial health, no debt, and expanding profit margins. The Q&A section reveals management's confidence despite minor headwinds, with no significant risks identified. Guidance is stable, and there is potential for upselling new products. The market cap suggests moderate volatility, aligning with a positive stock price reaction.
The earnings call highlights strong financial performance with increased gross margins, net income, and record ART cycles. Despite slightly lower EBITDA margins, revenue growth in fertility and pharmacy segments is robust. The Q&A reveals positive engagement, pipeline recovery, and no adverse impact from industry layoffs. Guidance remains optimistic, and demand for services is rising across company sizes. The market cap suggests moderate volatility, aligning with a positive stock price movement expectation of 2% to 8% in the short term.
The earnings report shows strong financial performance with a 16.5% revenue increase, improved gross margins, and a record high in ART cycles. Despite some uncertainties in utilization rates and macroeconomic factors, the company maintained a robust client base and expanded its offerings. The Q&A session reflected management's confidence in growth, with no slowdowns in RFP activities. Although there were some unclear responses, the overall positive financial metrics and optimistic guidance suggest a positive stock price movement, especially given the company's small-cap status.
The earnings call reveals solid financial performance with revenue growth, improved gross profit, and increased adjusted EPS. Despite a slight decline in net income, the overall financial health is strong, with no debt and substantial cash reserves. The Q&A section highlights optimism in new product adoption and international expansion, although some answers lacked clarity. Given the market cap of $2.7 billion, these factors suggest a moderate positive impact on the stock price, likely resulting in a 2% to 8% increase over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
